Cellestia Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Cellestia Biotech's estimated annual revenue is currently $3.6M per year.
- Cellestia Biotech's estimated revenue per employee is $201,000
Employee Data
- Cellestia Biotech has 18 Employees.
- Cellestia Biotech grew their employee count by -22% last year.
Cellestia Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Cellestia Biotech?
Cellestia is giving hope to cancer patients who have no other treatment or therapy options by developing innovative targeted therapies. Our drug discovery platform is built on a unique mode of action of targeting protein-protein interactions (PPI) with small molecules. Together with companion diagnostics, Cellestia provides a first-in-class solution for NOTCH-driven cancers. Our clinical candidate drug CB-103 is targeting orphan cancers such as cancer of the salivary gland (adenoid cystic carcinoma) and a subtype of childhood leukaemia. At the same time, we are continuing to expand our portfolio through (i) targeting large cancer indications with CB-103, such as breast cancer, and (ii) developing novel PPI inhibitors for additionnal oncology indications. Cellestia is a privately-owned clinical-stage biopharma company (phase I) led by an experienced team of scientists, drug developers and business professionals.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$3.6M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cellestia Biotech News
... Bayer AG, CELLESTIA BIOTECH SA, Boston Biomedical, OncoMed Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd., and many others.
Cellestia Biotech was borne out of this pioneering science, leading to the discovery of an anticancer drug with a new mode of action.
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 18 | N/A | N/A |
#2 | $2.1M | 19 | 6% | N/A |
#3 | $2M | 20 | 5% | N/A |
#4 | $2.9M | 20 | 5% | N/A |
#5 | $1.7M | 20 | 5% | N/A |